Drug intelligence / Profile preview

DEN vaccine F17

Development stage: Phase 2
Lead developer: Walter Reed Army Institute of Research
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

DEN vaccine F17 (also known as TDENV-LAV F17) is a tetravalent, live-attenuated dengue virus vaccine candidate. It was developed by the U.S. Army Medical Research and Materiel Command (USAMRMC) in collaboration with GSK Vaccines, with research conducted at the Walter Reed Army Institute of Research (WRAIR). The vaccine is composed of four live-attenuated dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) formulated as separate monovalent vaccines that are mixed prior to subcutaneous administration. It is designed to provide protective immunity against all four serotypes of the dengue virus. Clinical evaluation has included Phase I/II trials in Thai children, focusing on safety, immunogenicity, and the effects of booster doses.

Other names: Tetravalent dengue live attenuated virus formulation 17

Beyond the preview

Go deeper on DEN vaccine F17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DEN vaccine F17.

Explore the full profile